Photo of Clint Hermes

Clint Hermes

Clint Hermes draws on his deep experience as general counsel at two teaching hospitals to advise clients on regulatory, accreditation, and corporate governance matters in academic medicine. In addition, Clint also offers clients practical advice and insights on all regulatory and contracting aspects of human and animal research.

Note: This post was updated with new information on February 13, 2025.

On February 7, the National Institutes of Health (NIH) issued Supplemental Guidance to its 2024 NIH Grants Policy Statement, Indirect Cost Rates, purporting to cap indirect cost (also called facilities and administration, F&A) rates at 15% for all new grants issued as well as for go forward expenses for existing grants for educational purposes.  The purported basis for the cap, which is a quarter or less of the indirect rate charged by many universities, hospitals, and other research institutions, is that 15% is in line with the rate permitted by a number of foundations. Continue Reading Can the NIH Cap Indirect Cost Rates at 15%?

We will speak at a Strafford webinar providing guidance to life sciences companies and research institutions that are conducting or considering conducting clinical trials outside the United States.Continue Reading [WEBINAR] Conducting Clinical Trials Outside the U.S.: U.S. and Foreign Rules, Regulations, and Guidance